Author/Authors :
Park, In Seong Department of Internal Medicine - Pusan National University Hospital - Busan - Republic of Korea , Lee, Soo Bong Department of Internal Medicine - Yangsan Pusan National University Hospital - Yangsan - Republic of Korea , Song, Sang Heon Department of Internal Medicine - Pusan National University Hospital - Busan - Republic of Korea , Seong, Eun Young Department of Internal Medicine - Pusan National University Hospital - Busan - Republic of Korea , Kim, Il Young Department of Internal Medicine - Yangsan Pusan National University Hospital - Yangsan - Republic of Korea , Rhee, Harin Department of Internal Medicine - Pusan National University Hospital - Busan - Republic of Korea , Jeong Kim, Min Department of Internal Medicine - Yangsan Pusan National University Hospital - Yangsan - Republic of Korea , Lee, Dong Won Department of Internal Medicine - Yangsan Pusan National University Hospital - Yangsan - Republic of Korea
Abstract :
The 2016 American Heart Association/American College of
Cardiology guidelines advise the use of dual antiplatelet agents
for patients with acute coronary syndrome (ACS) (1). Ticagrelor
is a reversible oral antagonist of the ADP receptor P2Y12. It is
rapidly absorbed and metabolized by cytochrome P450 (CYP) 3A4.
Therefore, ticagrelor suggests a potential for drug interactions
with other CYP3A4 substrates (2).
Statins are recommended for preventing cardiovascular disease after ACS (3). These statins are associated with myalgia;
elevation of creatine phosphokinase (CK) concentrations; and
rarely, rhabdomyolysis. Rhabdomyolysis caused by statins is susceptible to occur when the renal function is impaired (4). Here we
describe a patient in whom ticagrelor-induced acute kidney injury (AKI) increased the serum concentration of statin and then,
eventually, led to concurrence of rhabdomyolysis.
Keywords :
Ticagrelor-induced acute kidney injury , serum concentration of statin , lead to concurrence of rhabdomyolysis
